Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.77 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | SCN4A | P35499 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8960677 | 0.87 | TACR1 (1.00) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL16321476 | 0.83 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4988525 | 0.83 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL18580091 | 0.83 | TACR1 (0.70) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4986022 | 0.81 | TACR1 (0.77) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5501540 | 0.80 | TACR1 (0.53) | TACR1IDO1 | |
| SCHEMBL9283193 | 0.79 | TSHR (0.62) | TACR1IDO1 | |
| SCHEMBL252456 | 0.79 | TACR1 (0.69) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL30715499 | 0.79 | TACR1 (0.69) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL252800 | 0.79 | TACR1 (0.69) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | TACR1 814/4885CACNA1F 4631/4885CACNA1D 4430/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | TACR1 814/4885CACNA1F 4631/4885CACNA1D 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.